Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: Concordance analysis and correlation with clinical outcome in heavily treated patients

Journal of Infectious Diseases

Volumn 188, Issue 2, 2003, Pages 194-201

  Torti, Carlo ^a   Quiros Roldan, Eugenia ^a   Keulen, Wilco ^f,g   Scudeller, Luigia ^b   Lo Caputo, Sergio ^c   Boucher, Charles ^f   Castelli, Francesco ^a   Mazzotta, Francesco ^c   Pierotti, Piera ^c   Been Tiktak, Anne Mieke ^g,h   Buccoliero, Giovanni ^d   De Gennaro, Michele ^e   Carosi, Giampiero ^a   Tinelli, Carmine ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d Santissima Annunziata Hospital   (Italy)

^e General Hospital   (Italy)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g Virology Networks   (Netherlands)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DEVICE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ODDS RATIO; PHENOTYPE; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0041314116     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376512     Document Type: Article

References (23)

1. Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-9.
2. Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antivir Ther 2000; 5:65-70.
3. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-93.
4. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-18.
5. BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2001; 2:276-313.
6. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 4 February 2002. Available at: http://aidsinfo.nih.gov/guidelines.
7. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendation of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-26.
8. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendation for the European setting. EuroGuidelines Group for HIV Resistance. AIDS 2001; 15:309-20.
9. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-79.
10. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-88.
11. Meynard J, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-36.
12. Haubrich R, Keiser P, Kemper C, et al. CCTG 575: randomized, prospective study of phenotype testing (pheno) versus standard of care (SOC) for patients failing antiretroviral therapy (ARV) [abstract 127]. In: Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001:123.
13. Vandamme AM, Houyez F, Banhegyi D, et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patients follow-up. Antivir Ther 2001; 6:21-39.
14. Harrigan PR, Montaner JSG, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-7.
15. Mazzotta F, Lo Caputo S, Torti C, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the genotipo-fenotipo dei resistenza (GenPherex) trail. J Acquir Immune Defic Syndr 2003; 32:268-80.
16. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
17. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
18. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition of AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41:(RR-17):1-19.
19. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-9.
20. Torti C, Quiros-Roldan E, Boucher CAB, et al. Head-to-head comparison of widely used HIV-1 drug resistance algorithms: RetroGram and VGI-TRUGENE HIV-1 [abstract 590-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:271.
21. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002; 15:247-77.
22. Shulman NS, Hughes MD, Winters MA, et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr 2002; 31:121-7.
23. Calvez V, Costagliola D, Descamps D, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther 2002; 7:211-8.